stockrowMerck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −130.7%
- Free cash flow
- +77.0%
- Total debt
- +50.4%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Revenue
Merck & Co., Inc.'s revenue for fiscal 2025 was $65.0B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $67.4B. Over the past ten years it has ranged from $39.1B (fiscal 2019) to $65.0B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. Merck & Co., Inc. ranks 3rd of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $65.0B | 1.31% |
| FY2024 | $64.2B | 6.74% |
| FY2023 | $60.1B | 1.40% |
| FY2022 | $59.3B | 21.72% |
| FY2021 | $48.7B | 17.31% |
| FY2020 | $41.5B | 6.13% |
| FY2019 | $39.1B | (7.50%) |
| FY2018 | $42.3B | 5.41% |
| FY2017 | $40.1B | 0.79% |
| FY2016 | $39.8B | 0.78% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $18.1B | 8.90% |
| Jun 2026 | $16.6B | 1.97% |
| Mar 2026 | $16.3B | (0.70%) |
| Dec 2025 | $16.4B | (5.07%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JNJ Johnson & Johnson compare | $99.3B |
| MRK Merck & Co., Inc. | $67.4B |
| ABBV AbbVie Inc. compare | $66.0B |
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| NVS Novartis AG compare | $57.4B |
| NVO Novo Nordisk A/S compare | $51.5B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on MRK
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement